Population study of disease burden, management, and treatment of bipolar disorder in Sweden: A retrospective observational registry study

Bipolar Disorders

Volumn 17, Issue 1, 2015, Pages 76-85

  Carlborg, Andreas ^a   Ferntoft, Lena ^b   Thuresson, Marcus ^c   Bodegard, Johan ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

^c STATISTICON AB   (Sweden)

Author keywords

Bipolar disorder; Incidence; Mortality; Prevalence; Socioeconomic factors

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; HALOPERIDOL; LAMOTRIGINE; LEVOMEPROMAZINE; LITHIUM; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; VALPROIC ACID; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CROSS-SECTIONAL STUDY; DEPRESSION; EDUCATION; FEMALE; HUMAN; INCIDENCE; INCOME; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SWEDEN; AGED; EPIDEMIOLOGY; MORTALITY; PATIENT CARE; PREVALENCE; PSYCHOLOGY; REGISTER; SOCIOECONOMICS; SPATIOTEMPORAL ANALYSIS; TRENDS;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT CARE MANAGEMENT; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; SOCIOECONOMIC FACTORS; SPATIO-TEMPORAL ANALYSIS; SWEDEN;

EID: 84921538423     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12234     Document Type: Article

References (45)

1. Prince M, Patel V, Saxena S et al. No health without mental health. Lancet 2007; 370: 859-877.
2. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
3. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60: 261-269.
4. Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552.
5. Goldberg JF, Harrow M, Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001; 158: 1265-1270.
6. McIntyre RS, Rosenbluth M, Ramasubbu R et al. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Ann Clin Psychiatry 2012; 24: 163-169.
7. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181.
8. Hawton K, Sutton L, Haw C, Sinclair J, Harriss L. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry 2005; 66: 693-704.
9. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf D. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63: 120-125.
10. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994; 72: 495-509.
11. World Health Organization. The Global Burden of Disease: 2004 Update. 2004. ISBN 9789241563710.
12. Grant BF, Stinson FS, Hasin DS et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66: 1205-1215.
13. Altamura AC, Armadoros D, Jaeger M, Kernish R, Locklear J, Volz HP. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Curr Med Res Opin 2008; 24: 2271-2282.
14. Parks J, Radke A, Parker G et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009; 35: 931-936.
15. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007; 9: 551-560.
16. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
17. Weisler RH, Calabrese JR, Thase ME et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69: 769-782.
18. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B, Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry 2009; 166: 476-488.
19. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International Trial 126). J Affect Disord 2008; 109: 251-263.
20. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464.
21. Hallinen T, Soini EJ, Granstrom O et al. Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012; 2: pii: e000915.
22. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2011.
23. Akiskal HS. The prevalent clinical spectrum of bipolar disorders: beyond DSM-IV. J Clin Psychopharmacol 1996; 16 (Suppl. 1): 4S-14S.
24. Kroon JS, Wohlfarth TD, Dieleman J et al. Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord 2013; 15: 306-313.
25. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. Int Rev Psychiatry 2010; 22: 437-452.
26. Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry 2010; 71: e14.
27. Arnold LM. Gender differences in bipolar disorder. Psychiatr Clin North Am 2003; 26: 595-620.
28. Bowden CL. Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv 2001; 52: 51-55.
29. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281-294.
30. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005; 66 (Suppl. 5): 11-16.
31. Keck PE Jr, McElroy SL, Strakowski SM et al. Outcome and comorbidity in first- compared with multiple-episode mania. J Nerv Ment Dis 1995; 183: 320-324.
32. US Food and Drug Administration (FDA), FDA Public Health Advisory. Worsening Depression and Suicidality in Patients Being Treated with Antidepressants, 2009. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm161696.htm [accessed March 2013].
33. Regier DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511-2518.
34. Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000; 2: 269-280.
35. Beyer J, Kuchibhatla M, Gersing K, Krishnan KR. Medical comorbidity in a bipolar outpatient clinical population. Neuropsychopharmacology 2005; 30: 401-404.
36. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844-850.
37. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002; 180: 227-233.
38. Kessing LV, Hansen HV, Hvenegaard A et al. Early Intervention Affective Disorders (EIA) Trial Group. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry 2013; 202: 212-219.
39. Fountoulakis KN, Kasper S, Andreassen O et al. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012; 262 (Suppl. 1): 1-48.
40. Ertugrul A, Meltzer HY. Antipsychotic drugs in bipolar disorder. Int J Neuropsychopharmacol 2003; 6: 277-284.
41. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012; 22: 339-346.
42. Mantere O, Suominen K, Arvilommi P, Valtonen H, Leppämäki S, Isometsä E. Clinical predictors of unrecognized bipolar I and II disorders. Bipolar Disord 2008; 10: 238-244.
43. Øiesvold T, Nivison M, Hansen V, Sørgaard KW, Østensen L, Skre I. Classification of bipolar disorder in psychiatric hospital. A prospective cohort study. BMC Psychiatry 2012; 12: 13.
44. Ekholm B, Ekholm A, Adolfsson R et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry 2005; 59: 457-464.
45. Vares M, Ekholm A, Sedvall GC, Hall H, Jonsson EG. Characterization of patients with schizophrenia and related psychoses: evaluation of different diagnostic procedures. Psychopathology 2006; 39: 286-295.